Gregg A. Lapointe

Gregg A. Lapointe, CPA has served as a member of the board of directors since August 2014. Mr. Lapointe is currently CEO of Cerium Pharmaceuticals, Inc., a specialty pharmaceutical company, a position he has held since April 2012. Mr. Lapointe also currently serves on the Board of Directors of Soligenix, Inc., a publicly traded biopharmaceutical company, SciClone Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical company, and Cambrooke Therapeutics, Inc., a privately held therapeutic nutrition company, and the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences. He has previously served on the Board of Directors of the Pharmaceuticals Research and Manufacturers of America (PhRMA) and Questcor Pharmaceuticals, Inc., and has been a member of the Corporate Council of NORD (National Organization for Rare Disorders) for several years. He previously served in varying roles for Sigma-Tau Pharmaceuticals, Inc, a private biopharmaceutical company, from September 2001 through February 2012, including Chief Operating Officer from November 2003 to April 2008 and Chief Executive Officer from April 2008 to February 2012. From May, 1996 to August, 2001, he served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc., a global manufacturer of paper machine clothing, advanced and filtration fabrics, filaments and drainage equipment). Prior to that, Mr. Lapointe spent several years in the Canadian medical products industry in both distribution and manufacturing. Mr. Lapointe began his career at Price Waterhouse. Mr. Lapointe received his B.A. degree in Commerce from Concordia University in Montreal, Canada, a graduate diploma in Accountancy from McGill University and his M.B.A. degree from Duke University. He is a C.P.A. in the state of Illinois and a Chartered Accountant in Ontario, Canada. Mr. Lapointe was selected to serve as a member of the Board of Directors because of his significant experience in the areas of global strategic planning and implementation, business development, corporate finance, and acquisitions, and his experience as an executive officer and board member in the pharmaceutical and medical products industries.